vancomycin hydrochloride Drug Patent Profile
✉ Email this page to a colleague
When do Vancomycin Hydrochloride patents expire, and when can generic versions of Vancomycin Hydrochloride launch?
Vancomycin Hydrochloride is a drug marketed by Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Pai Holdings Pharm, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Gland Pharma Ltd, Hainan Poly, Hainan Poly Pharm, Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Pharm Assoc, Sagent Pharms, Sandoz, Sandoz Inc, Teva Pharms Usa, Xellia Pharms Aps, Zhejiang Novus Pharm, Samson Medcl, and Baxter Hlthcare. and is included in fifty-three NDAs. There are five patents protecting this drug.
This drug has forty-seven patent family members in twenty-nine countries.
The generic ingredient in VANCOMYCIN HYDROCHLORIDE is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vancomycin Hydrochloride
A generic version of vancomycin hydrochloride was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17th, 1987.
Summary for vancomycin hydrochloride
International Patents: | 47 |
US Patents: | 5 |
Applicants: | 30 |
NDAs: | 53 |
Finished Product Suppliers / Packagers: | 25 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 423 |
Patent Applications: | 1,332 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for vancomycin hydrochloride |
What excipients (inactive ingredients) are in vancomycin hydrochloride? | vancomycin hydrochloride excipients list |
DailyMed Link: | vancomycin hydrochloride at DailyMed |
Recent Clinical Trials for vancomycin hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Center for Tumor Diseases, Heidelberg | Phase 2 |
University of Cologne | Phase 2 |
Heidelberg University | Phase 2 |
Pharmacology for vancomycin hydrochloride
Drug Class | Glycopeptide Antibacterial |
Medical Subject Heading (MeSH) Categories for vancomycin hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for vancomycin hydrochloride
Paragraph IV (Patent) Challenges for VANCOMYCIN HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FIRVANQ KIT | For Oral Solution | vancomycin hydrochloride | 25 mg/mL and 50 mg/mL | 208910 | 1 | 2020-05-18 |
US Patents and Regulatory Information for vancomycin hydrochloride
vancomycin hydrochloride is protected by five US patents and two FDA Regulatory Exclusivities.
Patents protecting vancomycin hydrochloride
Glycopeptide compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Glycopeptide compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Glycopeptide compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Glycopeptide compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting vancomycin hydrochloride
PATENT CHALLENGE
Exclusivity Expiration: ⤷ Try a Trial
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sagent Pharms | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 200837-002 | Sep 2, 2014 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-002 | Feb 15, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hikma | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 204360-001 | Oct 15, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for vancomycin hydrochloride
See the table below for patents covering vancomycin hydrochloride around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 7032488 | ⤷ Try a Trial | |
Tunisia | 2017000182 | GLYCOPEPTIDE COMPOSITIONS | ⤷ Try a Trial |
South Korea | 20230096142 | 글리코펩티드 조성물 (GLYCOPEPTIDE COMPOSITIONS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |